Veradigm Inc. (NASDAQ:MDRX) Shares Bought by Citadel Advisors LLC

Citadel Advisors LLC grew its stake in Veradigm Inc. (NASDAQ:MDRX – Get Rating) by 125.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,480,863 shares of the software maker’s stock after buying an additional 823,345 shares during the quarter. Citadel Advisors LLC owned 1.36% of Veradigm worth $22,553,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Nordea Investment Management AB lifted its holdings in Veradigm by 0.6% in the third quarter. Nordea Investment Management AB now owns 181,307 shares of the software maker’s stock valued at $2,809,000 after acquiring an additional 1,162 shares during the period. Bank of Montreal Can boosted its holdings in Veradigm by 3.6% during the first quarter. Bank of Montreal Can now owns 34,210 shares of the software maker’s stock worth $768,000 after buying an additional 1,198 shares in the last quarter. Macquarie Group Ltd. grew its position in Veradigm by 1.0% during the second quarter. Macquarie Group Ltd. now owns 155,176 shares of the software maker’s stock valued at $2,301,000 after buying an additional 1,589 shares during the period. Credit Suisse AG increased its holdings in Veradigm by 1.1% in the third quarter. Credit Suisse AG now owns 165,449 shares of the software maker’s stock valued at $2,519,000 after buying an additional 1,724 shares in the last quarter. Finally, CWM LLC raised its position in shares of Veradigm by 578.4% in the third quarter. CWM LLC now owns 2,103 shares of the software maker’s stock worth $32,000 after acquiring an additional 1,793 shares during the period. Hedge funds and other institutional investors own 99.76% of the company’s stock.

Get Veradigm alerts:

Veradigm Stock Down 1.2 %

NASDAQ MDRX opened at $14.25 on Thursday. Veradigm Inc. has a one year low of $13.59 and a one year high of $23.25. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.20 and a current ratio of 3.20. The business has a fifty day moving average price of $17.37 and a 200 day moving average price of $16.95. The company has a market cap of $1.56 billion, a P/E ratio of 33.14, a P/E/G ratio of 1.33 and a beta of 1.01.

Wall Street Analysts Forecast Growth

MDRX has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Veradigm from $19.00 to $20.00 and gave the company an “underweight” rating in a research note on Friday, November 18th. Argus raised Veradigm from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Wednesday, December 7th. They noted that the move was a valuation call. TheStreet raised shares of Veradigm from a “c+” rating to a “b-” rating in a research note on Wednesday, November 30th. SVB Securities reduced their price objective on shares of Veradigm from $24.00 to $17.00 in a research report on Wednesday, March 1st. Finally, Piper Sandler lowered shares of Veradigm from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $17.00 to $18.50 in a research report on Wednesday, February 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Veradigm currently has a consensus rating of “Hold” and an average price target of $20.90.

Insider Activity

In related news, SVP Tejal Vakharia sold 8,642 shares of the business’s stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $18.42, for a total transaction of $159,185.64. Following the transaction, the senior vice president now directly owns 222,604 shares in the company, valued at $4,100,365.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.29% of the company’s stock.

Veradigm Company Profile

(Get Rating)

Veradigm, Inc engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units.

Featured Articles

• Get a free copy of the StockNews.com research report on Veradigm (MDRX)
• Are Korn Ferry’s Results a Canary in the Employment Coal Mine?
• META Platforms May See its Biggest Opening Yet for New Highs
• Penny Stock Vinco Ventures Could Be Big Winner
• Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
• Should You Park Some Capital with Casey’s General Stores?

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veradigm Inc. (NASDAQ:MDRX – Get Rating).

Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.